Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis

    NEXT STORY
    Nurse Call Systems Market to Reach USD 2.79 Billion by 2026; Rising Incidence of Chronic Diseases to Propel Market, says Fortune Business Insights
    PREV STORY
    Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cancer Genetics, Inc. Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial

    Nearly half of the 50+ Immuno-Oncology Clinical Trials that CGI is supporting are combination ...

    author_avatar
    NASDAQ Market News

    Biocartis Group NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT

    THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF ...

    author_avatar
    NASDAQ Market News

    Sunesis Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) ...

    author_avatar
    NASDAQ Market News